2 enrolling by invitation. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Belumosudil 200 mg QD, Placebo - Rejection Chronic Renal | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 40 | 2025-09-11 | 2025-11-12 |
| Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 20 | 2022-07-28 | 2025-03-14 |
Fibrosis (1) · Kidney Failure, Chronic (1) · Rejection, Psychology (1)
Lung Diseases (2) · Lung Diseases, Interstitial (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Behavior (1) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosis (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
Fingolimod Hydrochloride (1) · Methylcellulose (1) · belumosudil (1)
The Methodist Hospital Research Institute (2)
United States (2)